Scope and Claim Construction for US Patent 12,576,034: Oral Tablet With Lactose/Cellulose Core and PVA Coating Without MCTs
US 12,576,034 claims an oral tablet composition built around a specific “core” excipient architecture (lactose monohydrate plus cellulose, plus disintegrant and lubricant) and a “coating formulation” defined by polyvinyl alcohol (PVA) with two functional/negative limitations: no medium chain triglycerides (MCTs) in the coating formulation, and no observable “color fading” after 48 hours at 40°C/75% RH. Dependent claims narrow compound A dosing, disintegrant identity (croscarmellose) and amounts, excipient ratios, lubricant identity (magnesium stearate), coating excipient levels (PEG and talc), and specific examples of core and coat compositions. The asserted method claims cover administering the claimed composition for multiple inflammatory and dermatologic indications, including plaque psoriasis, psoriatic arthritis, Behcet’s disease, and others.
What is claimed in US Patent 12,576,034 (composition and method scope)?
Independent Claim 1 is the primary scope driver. It ties together:
- Dosage form: an oral tablet.
- Two-part structure:
- Core composition comprising:
- compound A (or pharmaceutically acceptable salt),
- filler,
- disintegrant,
- lubricant.
- Coating formulation comprising polyvinyl alcohol.
- Core filler quantitative window:
- lactose monohydrate at 50% to 65% by weight of the pharmaceutical composition.
- cellulose at 15% to 40% by weight of the pharmaceutical composition.
- Coating constraints:
- coating formulation does not contain MCTs; and
- no color fading observed after 48 hours in an open dish stability chamber at 40°C and 75% relative humidity.
How broad is Claim 1 on excipients besides lactose and cellulose?
Claim 1 does not specify which disintegrant and lubricant are used in the independent claim. It only requires their presence. It also does not define whether cellulose is microcrystalline cellulose, powdered cellulose, or another cellulose grade. Those specifications are partially locked in dependent claims (e.g., croscarmellose, magnesium stearate, microcrystalline cellulose).
What does “no color fading” actually limit?
Claim 1 imposes a performance/observational limitation on the coating formulation: under set stress conditions (40°C/75% RH, 48 hours, open dish), the coated tablet must not show “color fading.” This is not a simple compositional exclusion. It can be used to argue that certain PVA-coating systems, even without MCTs, fall outside the claim if they produce visible fading under the test.
Which dependent claims narrow the formulation scope (filler/disintegrant/lubricant/coating)?
Compound A dose limits
- Claim 2: compound A present at 5% to 25% by weight of the pharmaceutical composition.
Disintegrant identity and level
- Claim 3: disintegrant is croscarmellose.
- Claim 4: croscarmellose present at 2% to 8% by weight of the pharmaceutical composition.
- Claim 5: ties croscarmellose to lactose:
- lactose monohydrate at 60% by weight of the core composition (note: this is core composition, not “pharmaceutical composition”),
- croscarmellose at 2% to 8% by weight of the core composition.
Lubricant identity and level
- Claim 6: lubricant is magnesium stearate.
- Claim 7: magnesium stearate present at 0.25% to 5% by weight of the pharmaceutical composition.
Coating formulation quantitative boundaries for key coat excipients
- Claim 8: PVA present at 35% to 45% by weight of the coating formulation.
- Claim 9: coating formulation can include “further excipients” including a coating agent, binder, lubricant, stabilizing agent, plasticizer, adhesive, glidant, diluent, or combinations.
- This is a permitted variability clause, but Claim 1 still retains the two coating constraints: no MCTs and no color fading at 48h/40°C/75% RH.
- Claim 10: permitted excipient includes polyethylene glycol (PEG).
- Claim 11: PEG present at 20% to 25% by weight of the coating formulation.
- Claim 12: permitted excipient includes talc.
- Claim 13: talc present at 10% to 15% by weight of the coating formulation.
Coloring agent composition option
- Claim 14: coating formulation can include one or more coloring agents.
- Claim 15: coloring agents present at 25% to 30% by weight of the coating formulation.
Detailed worked “core + coat” composition constraints (Claim 16 and 17)
These claims define full, concrete exemplified compositions that can be used as:
- reference points for claim charts,
- targets for infringement analysis (if a competitor matches closely), and
- narrowing benchmarks if a party wants to argue “design-around” by changing one element outside ranges.
Claim 16: core composition contains:
- compound A: 10% by weight of core
- lactose monohydrate: 60%
- microcrystalline cellulose: 26.25%
- croscarmellose: 3%
- magnesium stearate: 0.75%
Claim 17: coating formulation contains:
- PVA: 40% by weight of coat
- PEG: 20%
- talc: 15%
- mixture of coloring agents: 25%
Practical effect: Claim 16/17 are narrower than Claim 1. They are often the easiest to map to product-specific compositions, assuming the competitor’s formulation aligns.
What method-of-use scope exists (which diseases are explicitly covered)?
Claim 18: broad indication list
Claim 18 requires administration of the composition of Claim 1 where the disease is selected from:
- psoriasis (including plaque-type in Claim 19),
- arthritis,
- dermatitis,
- acne,
- dermatomyositis,
- ulcerative colitis,
- Behcet’s disease,
- Crohn’s disease,
- sarcoidosis,
- uveitis,
- rosacea,
- lichen planus.
This is a typical inflammatory/immune-mediated and dermatologic umbrella. It is not limited to oral plaque psoriasis only; Claim 19 adds that explicit narrowing.
Claim 19: plaque-type psoriasis
Claim 20: psoriatic arthritis
Claim 21: Behcet’s disease
Infringement logic: method claims require (i) the accused product to meet composition Claim 1, and (ii) the administration to match one of the listed conditions. For Paragraph IV cases, labeling and promotional claims can matter to whether the method is “carried out” by the parties.
How would a court likely construe key “gating” limitations in Claim 1?
1) Is “cellulose” in Claim 1 limited to microcrystalline cellulose?
Independent Claim 1 says “cellulose.” Dependent Claim 16 specifies microcrystalline cellulose. Under typical claim construction principles, dependent specificity does not rewrite independent scope. Therefore, Claim 1 likely covers cellulose more broadly than microcrystalline cellulose, while Claim 16 covers an explicit grade.
2) Does “filler comprises lactose monohydrate and cellulose” require both as part of the filler or the overall composition?
Claim 1 says filler comprises:
- lactose monohydrate 50% to 65% by weight of the pharmaceutical composition, and
- cellulose 15% to 40% by weight of the pharmaceutical composition.
That phrasing ties the percentages to the entire pharmaceutical composition, even though it is located within the “filler comprises” clause. The safe infringement-reading is that the overall tablet contains those weight fractions of lactose and cellulose.
3) “Coating formulation comprises polyvinyl alcohol” plus “does not contain MCTs”
Competitors cannot simply swap out other excipients while keeping MCTs out. They must also address the color fading test and the PVA presence requirement.
4) The “no color fading after 48 hours at 40°C/75% RH in an open dish” constraint
This functions like:
- a negative compositional plus
- a conditional stability/performance limitation.
Even if a coating uses PVA and excludes MCTs, a failure in the observation test can be argued to fall outside Claim 1.
What is the practical patent landscape risk posed by US 12,576,034 (likely claim breadth vs. typical design-around)?
The risk concentration
US 12,576,034 concentrates risk in formulation and coating stability rather than in the pharmacological mechanism of compound A. That usually creates:
- composition infringement pathways if the accused tablet matches the lactose/cellulose windows and uses PVA-based coatings without MCTs and with acceptable color stability; and
- hard-to-escape performance defenses for applicants trying to maintain the same aesthetic or stability profile.
Design-around leverage points
A generic or follow-on manufacturer attempting to avoid Claim 1 while keeping a similar therapeutic profile can target:
- PVA coating substitution: replacing PVA in coating may avoid the “comprises polyvinyl alcohol” limitation.
- MCT inclusion: adding MCT is likely a direct violation. Still, some applicants may keep MCTs out but adjust other coat excipients to trigger/avoid the “no fading” observation. That is not a straightforward design-around because the claim uses a test outcome, not a single ingredient exclusion.
- Adjusting lactose/cellulose ratios: moving lactose monohydrate outside 50%–65% or cellulose outside 15%–40% by weight of the pharmaceutical composition.
- Disintegrant/lubricant choices: dependent claims add constraints (croscarmellose, magnesium stearate). Even if Claim 1 does not require specific identities, Claim 1 requires disintegrant and lubricant presence. If those are swapped, infringement of dependent claims may be avoided; Claim 1 might still be at risk depending on how the disintegrant/lubricant map.
Where competitors are most exposed
- If competitors replicate the full set of dependent constraints (croscarmellose, magnesium stearate, PEG and talc levels, coloring agent percentages), claims 1-17 become cumulatively easier for a patentee to chart.
- If competitors sell tablets formulated around similar excipient architecture and coating stability behavior, they face both:
- literal infringement arguments, and
- increased likelihood of being caught in discovery via formulation specs, batch records, or stability studies.
How would claim scope interact with regulatory and FDA Orange Book status (generic entry risk)?
This is not answerable from the claim text alone. Orange Book listing depends on:
- the drug product linked to compound A,
- whether US 12,576,034 is listed for that NDA/ANDA,
- the listed dosage form and strength.
Still, the claim’s structure suggests it would be a typical “composition + coating + performance” patent that can be tied to a specific listed tablet presentation.
Generic entry mechanics likely at play in practice (when this type of patent is Orange Book listed):
- An ANDA applicant may file a Paragraph IV certification attacking whether the generic meets the listed composition/coating limitations.
- A patentee can use formulation disclosures and stability data to argue that the generic’s coated tablet fails the “no color fading” requirement or contains prohibited excipients (MCTs).
What to expect in litigation: strongest infringement hooks and typical defenses
Strongest infringement hooks
- Tablet structure proof: core and coating formulation composition matches the defined excipient classes and quantitative windows.
- Test outcome evidence: the accused product shows color fading at 48 hours under the specified conditions.
- Component mapping: evidence that lactose monohydrate and cellulose in the marketed tablet fall within the weight ranges.
Likely defenses
- Non-infringement by formulation differences: changing lactose/cellulose ratio or coating composition (PVA replacement, MCT inclusion/exclusion depending on theory).
- Non-infringement by test result: if the accused product passes the stability observation, an attack can focus on whether the patentee’s test is comparable and whether “no color fading” is satisfied.
- Claim scope disputes: whether “cellulose” is limited, and whether “color fading” is a subjective observation that requires a defined method.
Patent strength assessment for licensing or investment decisions (claim density and narrow/functional balance)
US 12,576,034’s strength comes from a combination of:
- numerical excipient constraints (lactose, cellulose, PVA, PEG, talc, coloring agents),
- ingredient identity requirements in dependents (croscarmellose, magnesium stearate, microcrystalline cellulose),
- negative limitation on MCTs, and
- a functional stability/performance observation (“no color fading after 48 hours at 40°C/75% RH”).
That combination often increases the cost of “nearby” formulation changes because a generic cannot only alter one ingredient; it must preserve both the composition windows and the observed coating behavior.
Main weakness in enforceability is that Claim 1 depends on:
- the accused product being an “oral tablet” with the same structural core/coating framework, and
- the ability to reproduce the observation test and demonstrate failure or satisfaction under the same conditions.
Key takeaways
- US 12,576,034 claims a specific tablet formulation architecture: lactose monohydrate plus cellulose in defined weight windows, disintegrant and lubricant in the core, and a PVA coating with no MCTs and no observed color fading after 48 hours at 40°C/75% RH.
- Dependent claims further narrow to compound A 5%–25%, croscarmellose disintegrant at 2%–8%, magnesium stearate at 0.25%–5%, plus defined PEG and talc levels and optional coloring agent percentages in the coat.
- The method claims cover administering the claimed composition to patients with a multi-indication list centered on dermatologic and inflammatory diseases, including plaque psoriasis, psoriatic arthritis, and Behcet’s disease.
- For generic entry risk, the most exposed products are those that match both the excipient ratio windows and the PVA coat stability behavior under the specified test conditions.
FAQs
- Does changing the disintegrant avoid infringement if Claim 1 is still met?
- How does the “no color fading after 48 hours” limitation affect design-around strategies for coated tablets?
- Are “cellulose” and “microcrystalline cellulose” treated as the same for Claim 1 coverage?
- What matters more for method claims: the accused product composition or the indication on label and promotion?
- If a competitor uses PVA but replaces PEG or talc, can it avoid dependent claims while still risking Claim 1?
References (APA)
- United States Patent No. 12,576,034 (claims excerpt provided by user).
